Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02158052 · ClinicalTrials.gov registry record · NA
Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 2
- Enrollment target
NCT02158052: Completed NA study, sponsored by Massachusetts General Hospital.
NCT02158052 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 2 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02158052, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
Study Summary
This pilot trial offers the unique opportunity for both the treatment of multiple myeloma or systemic AL amyloidosis for which hematopoietic stem cell transplantation would be ordinarily indicated and the reversal of end-stage renal failure, while avoiding the risks associated with long-term standard anti-rejection therapy used in renal transplantation. The primary objectives of this study are to assess renal allograft tolerance (that is, the acceptance of the kidney without the need for anti-rejection therapy), assess anti-tumor response rates in multiple myeloma and AL amyloidosis, and assess complication rates for genetically (HLA) matched related donor combined bone marrow and kidney transplantation using a low dose total body irradiation based preparative regimen.
Primary Outcome
The Primary Outcome is: the incidence of renal allograft rejection at 6 months post-transplant
Interventions
- DRUG Tacrolimus
- DRUG Equine Anti-thymocyte globulin
- PROCEDURE Kidney transplant from a related donor
- DRUG Bone marrow transplant from a related donor
- RADIATION Total body irradiation 400 centigray (200 cGy X 2)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2015-02 |
| Est. Completion | 2021-06-22 |
| Phase | NA |
What the finished NCT02158052 record still lists
NCT02158052 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 5 interventions - of which Tacrolimus is the first listed.
NCT02158052 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02158052 about?
NCT02158052 is a clinical study titled "Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease". This pilot trial offers the unique opportunity for both the treatment of multiple myeloma or systemic AL amyloidosis for which hematopoietic stem cell transplantation would be ordinarily indicated and the reversal of end-stage renal failure, while avoiding the risks associated with long-term standar...
What is the current status of trial NCT02158052?
This trial is currently completed. It is a NA study. The enrollment target is 2 participants. The study started on 2015-02. Estimated completion is 2021-06-22.
What interventions are being tested in trial NCT02158052?
The interventions under investigation include: Tacrolimus (DRUG), Equine Anti-thymocyte globulin (DRUG), Kidney transplant from a related donor (PROCEDURE), Bone marrow transplant from a related donor (DRUG), Total body irradiation 400 centigray (200 cGy X 2) (RADIATION).
Who is sponsoring clinical trial NCT02158052?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02158052's enrollment target sits among peer trials
2 1997th of 2000 the lowest of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia